Malignant Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We report here the results of analysis of TPR-MET expression in cell lines derived from human gastric tumors and 22 biopsy samples of human gastric mucosa showing cancer or precursor lesions.
|
2052572 |
1991 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present study was carried out to evaluate the relationship between c-MET expression and cancer cell proliferation or effect of cancer therapy.
|
9772281 |
1998 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
TPR-MET, a transforming counterpart of the c-MET proto-oncogene detected in experimental and human cancer, results from fusion of the MET kinase domain with a dimerization motif encoded by TPR.
|
10435641 |
1999 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The selectively strong synergy of rAd-MET and rMETase on cancer cells allows reduced levels of each agent to be used, thus decreasing potential side effects.
|
10825143 |
2000 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Both cancer cell lines expressed Met protein and did not express hepatocyte growth factor (HGF).
|
11029504 |
2000 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Both SF/HGF and MET expression have also been described to correlate with the malignancy grade of human gliomas.
|
11296484 |
2001 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
HGF and c-Met proteins were expressed in cancer and stromal cells, with autocrine and paracrine patterns.
|
11328532 |
2001 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recombinant adenovirus-encoding MET gene-SeMET treatment thereby offers a new paradigm for cancer gene therapy.
|
11559554 |
2001 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC.
|
11705871 |
2001 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The results suggest that constitutive overexpression of Met receptor may negatively regulate the malignancy of certain human lung cancer cells.
|
11795945 |
2002 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that MET might be one of the long sought oncogenes controlling progression of primary cancers to metastasis.
|
12460923 |
2002 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer.
|
12620387 |
2003 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Aberrant signalling through the hepatocyte growth factor/scatter factor receptor Met has been implicated in various aspects of the development of human cancer including the promotion of tumour invasion, angiogenesis and metastasis.
|
14627992 |
2003 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The cancer gene profiles contained both known cancer-associated genes (MET, galectin-3) and previously unidentified genes.
|
15319714 |
2004 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Studies have shown that overexpression of mutant forms of MET cause cancer in mice.
|
15738393 |
2005 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MET protein expression showed no apparent association with the presence of MET(T1010I), and the clinical features of the patients with cancer with MET(T1010I) were similar to those of patients whose cancer did not harbor MET(T1010I).
|
15767811 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The MET oncogene drives a genetic programme linking cancer to haemostasis.
|
15772665 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This review summarizes the structure and functions of c-MET, with particular emphasis on its role in upper aerodigestive malignancies.
|
16050800 |
2005 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here, we have examined a panel of 110 B-cell malignancies for MET expression, which, apart from MM (48%), was found to be largely confined to diffuse large B-cell lymphomas (DLBCLs) (30%).
|
16189274 |
2006 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The Met receptor tyrosine kinase (RTK) regulates epithelial remodeling, dispersal, and invasion and is deregulated in many human cancers.
|
16227611 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We also found that skeletrophin downregulated transcription of the Met oncogene, which encodes the hepatocyte growth factor receptor and plays a role in the determination of the invasive phenotype of many malignant tumors.
|
16715130 |
2006 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Based on these observations, we concluded that despite the fact that ARAF, CRAF and MET are actively expressed, alterations of these genes are rare in PTC and unlikely to play a perceptible role in the molecular pathogenesis of this type of human malignancy.
|
16896265 |
2006 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Overexpressed or activated hepatocyte growth factor receptor, encoded by the MET proto-oncogene, was found in the majority of colorectal carcinomas (CRCs), whose stepwise progression to malignancy requires transcriptional activation of beta-catenin.
|
16953230 |
2007 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression of Met, the Hepatocyte Growth Factor receptor, has been shown to have prognostic value in numerous types of cancer including breast, gastric, cervical and head and neck carcinomas.
|
17260003 |
2007 |